Effect of spironolactone and captopril on nitric oxide and S-nitrosothiol formation in kidney of L-NAME-treated rats

Kidney International

Volumn 70, Issue 1, 2006, Pages 170-176

  Pechanova, O ^a,c   Matuskova, J ^b   Capikova, D ^a   Jendekova, L ^a   Paulis, L ^a,b   Simko, F ^b  

^a INSTITUTE OF CHEMISTRY   (Slovakia)

^b Physics and Informatics   (Slovakia)

^c INSTITUTE OF PHYSIOLOGY   (Czech Republic)

Author keywords

Captopril; Hypertension; Kidney; NO synthase; S nitrosothiols; Spironolactone

Indexed keywords

ALDOSTERONE RECEPTOR; CAPTOPRIL; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; N(G) NITROARGININE METHYL ESTER; NITRIC OXIDE SYNTHASE; S NITROSOTHIOL; SPIRONOLACTONE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIOXIDANT ACTIVITY; ARTICLE; CONTROLLED STUDY; DRUG EFFECT; ENZYME ACTIVITY; ENZYME INHIBITION; KIDNEY DISEASE; KIDNEY FUNCTION; KIDNEY PARENCHYMA; NONHUMAN; OXIDATIVE STRESS; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; SYSTOLIC BLOOD PRESSURE;

ALDOSTERONE ANTAGONISTS; ANGIOTENSIN-CONVERTING ENZYME INHIBITORS; ANIMALS; ANTIHYPERTENSIVE AGENTS; BLOOD PRESSURE; CAPTOPRIL; ENZYME INHIBITORS; HYPERTENSION, RENAL; KIDNEY; MALE; NG-NITROARGININE METHYL ESTER; NITRIC OXIDE; NITRIC OXIDE SYNTHASE TYPE III; RATS; RATS, WISTAR; S-NITROSOTHIOLS; SPIRONOLACTONE;

EID: 33745711905     PISSN: 00852538     EISSN: 15231755     Source Type: Journal    
DOI: 10.1038/sj.ki.5001513     Document Type: Article

References (44)

1. Simko F, Simko J. Heart failure and angiotensin converting enzyme inhibition: problems and perspectives. Physiol Res 1999; 48: 1-8.
2. Lijnen P, Petrov V. Induction of cardiac fibrosis by aldosterone. J Mol Cell Cardiol 2000; 32: 865-879.
3. White WB, Duprez D, St Hillaire R et al. Effects of the selective aldosterone blocker eplerenone versus the calcium antagonist amlodipine in systolic hypertension. Hypertension 2003; 42: 1021-1026.
4. Pitt B, Zannad F, Remme WJ et al. The effect of spironolactone on morbidity and mortality in patients with severe heart failure. Randomized aldactone evaluation study investigators. N Engl J Med 1999; 341: 709-717.
5. Sato A, Saruta T. Aldosterone escape during angiotensin-converting enzyme inhibitor therapy in essential hypertensive patients with left ventricular hypertrophy. Int Med Res 2001; 29: 13-21.
6. Epstein M. Aldosterone and the hypertensive kidney: its emerging role as a mediator of progressive renal dysfunction: a paradigm shift. J Hypertens 2001; 19: 829-842.
7. Francis J, Weiss RM, Wei SG et al. Central mineralocorticoid receptor blockade improves volume regulation and reduces sympathetic drive in heart failure. Am J Physiol Heart Circ Physiol 2001; 281: H2241-H2251.
8. Sun Y, Zhang J, Lu L et al. Aldosterone-induced inflammation in the rat heart. Role of oxidative stress. Am J Pathol 2002; 161: 1773-1781.
9. Kunes J, Hojna S, Kadlecova M et al. Altered balance of vasoactive systems in experimental hypertension: the role of relative NO deficiency. Physiol Res 2004; 53: S23-S34.
10. Pechanova O, Bernatova I, Pelouch V et al. Protein remodelling of the heart in NO-deficient hypertension: the effect of captopril. J Mol Cell Cardiol 1997; 29: 3365-3374.
11. Bernatova I, Pechanova O, Simko F. Captopril prevents NO-deficient hypertension and left ventricular hypertrophy without affecting nitric oxide synthase activity in rats. Physiol Res 1996; 45: 311-316.
12. Hropot M, Grotsch H, Klaus E et al. Ramipril prevents the detrimental sequels of chronic NO synthase inhibition in rats: hypertension, cardiac hypertrophy and renal insufficiency. Naunyn-Schmiedeberg's Arch Pharmacol 1994; 350: 646-652.
13. Myers PR, Minor Jr RL, Guerra Jr R et al. Vasorelaxant properties of the endothelium-derived relaxing factor more closely resemble S-nitrosocysteine than nitric oxide. Nature 1990; 345: 161-163.
14. Ignarro LJ, Lippton H, Edwards JC et al. Mechanism of vascular smooth muscle relaxation by organic nitrates, nitrites, nitroprusside and nitric oxide: evidence for the involvement of S-nitrosothiols as active intermediates. J Pharmacol Exp Ther 1981; 218: 739-749.
15. Simko F, Matuskova J, Luptak I et al. Effect of simvastatin on remodeling of the left ventricle and aorta in L-NAME-induced hypertension. Life Sci 2004; 74: 1211-1224.
16. Bernatova I, Pechanova O, Simko F. Effect of captopril in L-NAME-induced hypertension on the rat myocardium, aorta, brain and kidney. Exp Physiol 1999; 84: 1095-1105.
17. Gallego M, Espina L, Vegas L et al. Spironolactone and captopril attenuates isoproterenol-induced cardiac remodeling in rats. Pharmacol Res 2001; 44: 311-316.
18. Brilla CG, Matsubara LS, Weber KT et al. Anti-aldosterone treatment and the prevention of myocardial fibrosis in primary and secondary hyperaldosteronism. J Mol Cell Cardiol 1993; 25: 563-575.
19. Bartosz M, Kedziora J, Bartosz G et al. Antioxidant and prooxidant properties of captopril and enalapril. Free Rad Biol Med 1997; 23: 729-735.
20. Bernatova I, Pechanova O, Pelouch V, Simko F. Regression of chronic L-NAME-treatment-induced left ventricular hypertrophy: effect of captopril. J Mol Cell Cardiol 2000; 32: 177-185.
21. Torok J, Babal P, Matuskova J et al. Impaired endothelial function of thoracic aorta in hereditary hypertriglyceridemic rats. Ann N Y Acad Sci 2002; 967: 469-475.
22. Schafer A, Fraccarollo D, Hildemann S et al. Inhibition of platelet activation in congestive heart failure by aldosterone receptor antagonism and ACE inhibition. Thromb Haemost 2003; 89: 1024-1030.
23. Quaschning T, Ruschitzka F, Shaw S et al. Aldosterone receptor antagonism normalizes vascular function in liquorice-induced hypertension. Hypertension 2001; 37: 801-805.
24. Pereira MLM, Mandarim-de-Lacerda CA. Effect of antihypertensive drugs on the myocardial microvessels in rats with nitric oxide blockade. Pathol Res Pract 2000; 196: 305-311.
25. Akuzawa N, Nakamura T, Kurashina T et al. Antihypertensive agents prevent nephrosclerosis and left ventricular hypertrophy induced in rats by prolonged inhibition of nitric oxide synthesis. Am J Hypertens 1998; 11: 697-707.
26. Simko F, Simko J. The potential role of nitric oxide in the hypertrophic growth of the left ventricle. Physiol Res 2000; 49: 37-46. Review.
27. Stamler JS, Jaraki O, Osborne J et al. Nitric oxide circulates in mammalian plasma primarily as an S-nitroso adduct of serum albumin. Proc Natl Acad Sci USA 1992; 89: 7674-7677.
28. Pechanova O, Bernatova I. Effect of captopril on cyclic nucleotide concentrations during long-term NO synthase inhibition. Physiol Res 2000; 49: 55-63.
29. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type 1 receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627.
30. Devlin AM, Brosnan MJ, Graham D et al. Vascular smooth muscle cell polyploidy and cardiomyocyte hypertrophy due to chronic NOS inhibition in vivo. Am J Physiol 1998; 274: H52-H59.
31. Takemoto M, Egashira K, Tomita H et al. Chronic angiotensin-converting enzyme inhibition and angiotensin II type receptor blockade: effects on cardiovascular remodeling in rats induced by the long-term blockade of nitric oxide synthesis. Hypertension 1997; 30: 1621-1627.
32. Hao L, Kanno Y, Fukushima R et al. Effects of eplerenone on heart and kidney in two-kidney, one-clip rats. Am J Nephrol 2004; 24: 54-60.
33. Farquharson CA, Struthers AD. Spironolactone increases nitric oxide bioactivity, improves endothelial vasodilator dysfunction, and suppresses vascular angiotensin I/angiotensin II conversion in patients with chronic heart failure. Circulation 2000; 101: 594-597.
34. Liu YJ, Nakagawa Y, Toya K et al. Effects of spironolactone on systolic blood pressure in experimental diabetic rats. Kidney Int 2000; 57: 2064-2071.
35. Fujihara CK, Mattar AL, Vieira JM et al. Evidence for the existence of two distinct functions for the inducible NO synthase in the rat kidney: effect of aminoguanidine in rats with 5/6 ablation. J Am Soc Nephrol 2002; 13: 2278-2287.
36. Aiello S, Noris M, Todeschini M et al. Renal and systemic nitric oxide synthesis in rats with renal mass reduction. Kidney Int 1997; 52: 171-181.
37. Pereira LMM, Mandarim-de-Lacerda CA. Glomerular profile numerical density per area and mean glomerular volume in rats submitted to nitric oxide synthase blockade. Histol Histopathol 2001; 16: 15-20.
38. Hropot M, Langer KH, Wiemer G et al. Angiotensin II subtype AT1 receptor blockade prevents hypertension and renal insuficiency induced by chronic NO-synthase inhibition in rats. Naunyn-Schmiedeberg's Arch Pharmacol 2003; 367: 312-317.
39. Khattab MM, Mostafa A, Al-Shabanah O. Effects of captopril on cardiac and renal damage, and metabolic alterations in the nitric oxide-deficient hypertensive rat. Kidney Blood Press Res 2005; 28: 243-250.
40. Bredt DS, Snyder SH. Isolation of nitric oxide synthetase, a calmodulin-requiring enzyme. Proc Natl Acad Sci USA 1990; 87: 682-685.
41. Ellman GL. Tissue sulfhydryl groups. Arch Biochem Biophys 1959; 82: 70-77.
42. Saville B. A scheme for colorimetric determination of microgram amounts of thiols. Analyst 1958; 83: 670-672.
43. Tietze F. Enzymic method for quantitative determination of nanogram amounts of total oxidized glutathione: applications to mammalian blood and other tissues. Anal Biochem 1969; 27: 502-522.
44. Minamiyama Y, Takemura S, Inoue M. Effect of thiol status on nitric oxide metabolism in the circulation. Arch Biochem Biophys 1997; 341: 186-192.